Literature DB >> 21287186

Psychosocial aspects in myasthenic patients treated by plasmapheresis.

Yu-Tai Chen1, Yuanmay Chang, Hou-Chang Chiu, Jiann-Horng Yeh.   

Abstract

Knowledge about the postintervention psychosocial status of myasthenia gravis (MG) is limited and based on questionnaire studies. In this study, the effects of improvement in muscle strength with plasmapheresis treatment on both quality of life (QoL) and psychological status of MG patients were studied. Between January 2008 and December 2009, 29 MG patients were enrolled to receive one course of plasmapheresis treatment. Differences in baseline and posttherapy clinical, laboratory, and psychosocial measures were determined. The mean MG score decreased from 7.8 points at baseline to 4.2 after plasmapheresis, accompanied by the mean antibody clearance of 56%. Psychosocial tests showed significant pre- and posttherapy differences in illness identity (mean scores 23.62 and 20.79 points, respectively) and disability (mean scores 11.28 and 7.63 points, respectively) (p < 0.01). No significant differences were found for the other indices. Although both anxiety and depression scores did not differ significantly, there was a clear change in patients, as evidenced by their decreases in severity after treatment. The mean mental components scores of QoL were still less than 40 after treatment, indicating that myasthenic patients need assistance in adapting to their disease. Thus, although plasmapheresis treatment achieved immediate improvement of myasthenic symptoms, reduced disability, and better illness identity, both emotional status and QoL did not differ significantly after intervention. Systematical evaluation for patients' illness perceptions and emotional problems are warranted and related strategies should be taken for long-term stabilization of psychosocial function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21287186     DOI: 10.1007/s00415-011-5913-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Epidemiologic evidence for a changing natural history of myasthenia gravis.

Authors:  L H Phillips; J C Torner
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

Review 2.  Long-term outcome and quality of life after thymectomy for myasthenia gravis.

Authors:  C Busch; A Machens; U Pichlmeier; T Emskötter; J R Izbicki
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

3.  Severity of mood, self-evaluative, and vegetative symptoms of depression in myasthenia gravis.

Authors:  R H Paul; R A Cohen; J M Goldstein; J M Gilchrist
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2000       Impact factor: 2.198

4.  Quality of life in multiple sclerosis: the disability and impact profile (DIP).

Authors:  G J Lankhorst; F Jelles; R C Smits; C H Polman; D J Kuik; L E Pfennings; L Cohen; H M van der Ploeg; P Ketelaer; L Vleugels
Journal:  J Neurol       Date:  1996-06       Impact factor: 4.849

5.  An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

Authors:  D B Sanders; I K Hart; R Mantegazza; S S Shukla; Z A Siddiqi; M H V De Baets; A Melms; M W Nicolle; N Solomons; D P Richman
Journal:  Neurology       Date:  2008-04-23       Impact factor: 9.910

6.  Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group.

Authors:  N Murphy; C Confavreux; J Haas; N König; E Roullet; M Sailer; M Swash; C Young; J L Mérot
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-10       Impact factor: 10.154

7.  Remission of myasthenia gravis following plasma-exchange.

Authors:  A J Pinching; D K Peters
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

8.  Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis.

Authors:  A Jønsson; J Dock; M H Ravnborg
Journal:  Acta Neurol Scand       Date:  1996-04       Impact factor: 3.209

Review 9.  Coping with neuroimmunological diseases.

Authors:  Thomas Klauer; Wolfgang Schneider; Uwe K Zettl
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

10.  Coping with myasthenia gravis and implications for psychotherapy.

Authors:  S Doering; T Henze; G Schüssler
Journal:  Arch Neurol       Date:  1993-06
View more
  3 in total

1.  Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia).

Authors:  Ivana Z Basta; Tatjana D Pekmezović; Stojan Z Perić; Darija B Kisić-Tepavčević; Vidosava M Rakočević-Stojanović; Zorica D Stević; Dragana V Lavrnić
Journal:  Neurol Sci       Date:  2012-08-09       Impact factor: 3.307

2.  Validation of the MG-DIS: a disability assessment for myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Silvia Schiavolin; Carlo Antozzi; Greta Brenna; Lorenzo Maggi; Renato Mantegazza
Journal:  J Neurol       Date:  2016-03-01       Impact factor: 4.849

3.  Illness perception characteristics and influencing factors in adult patients with myasthenia gravis in China.

Authors:  Le Xu; Xia Wang; Yafeng Cui; Yanghua Tian; Nong Zhou; Juanjuan Zhang; Hiaxia Ji; Xiumei Cheng; Qin Zhang; Qingfeng Li; Panpan Hu; Long Zhang
Journal:  Brain Behav       Date:  2021-12-12       Impact factor: 2.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.